Sign inJoin waitlistJoin the waitlist

Yasir Elamin

Program Director, Fellowship Program · University of Texas M D Anderson Cancer Center

Credentials: · ·

History

University of Texas M D Anderson Cancer Center Fellowship
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2015–2017
BEAUMONT HEALTH
2013–2015
Medical Oncology
2011–2013
Galway University Hospital
2009–2011
Federal Ministry of Health
2005–2007
Doctor of Medicine
2001–2005

Research

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Cancer Discovery · 2018 · 1,415 citations
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Nature Medicine · 2021 · 558 citations
Structure-based classification predicts drug response in EGFR-mutant NSCLC
Nature · 2021 · 421 citations

John Heymach
44 papers
Xiuning Le
36 papers
Jianjun Zhang
32 papers
Don Gibbons
26 papers
Marcelo Negrao
19 papers
Tina Cascone
19 papers
Mehmet Altan
18 papers · 1 as a fellow
Anne Tsao
17 papers
George Blumenschein
17 papers
Ferdinandos Skoulidis
16 papers
Ara Vaporciyan
14 papers
Carl Gay
14 papers · 1 as a fellow

Clinical trials

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2026–2030
Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer
Principal investigator · Withdrawn · Phase 2
M.D. Anderson Cancer Center
2021–2023
Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
Principal investigator · Active not recruiting · Phase 1
M.D. Anderson Cancer Center
2021–2027
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
Principal investigator · Completed · Phase 1
M.D. Anderson Cancer Center
2020–2023